Abstract
Over the last decades, accumulating data have advanced our understanding of the mechanism of action of tumor suppressor proteins and therapeutic strategies to restore tumor suppressor pathways have emerged as a promising approach for cancer therapy. Based on our recent findings on bridging integrator-1 (BIN1), we outline potential advantages and disadvantages of chemical activation of tumor suppressors.
Original language | English (US) |
---|---|
Article number | e991225 |
Journal | Molecular and Cellular Oncology |
Volume | 2 |
Issue number | 3 |
DOIs | |
State | Published - Jul 3 2015 |
Keywords
- BIN1
- RB1
- p53
- small-molecule inhibitor
- tumor suppressor
ASJC Scopus subject areas
- Molecular Medicine
- Cancer Research